[go: up one dir, main page]

BRPI0607817A2 - processo para a preparação de compostos macrocìclicos - Google Patents

processo para a preparação de compostos macrocìclicos

Info

Publication number
BRPI0607817A2
BRPI0607817A2 BRPI0607817-6A BRPI0607817A BRPI0607817A2 BR PI0607817 A2 BRPI0607817 A2 BR PI0607817A2 BR PI0607817 A BRPI0607817 A BR PI0607817A BR PI0607817 A2 BRPI0607817 A2 BR PI0607817A2
Authority
BR
Brazil
Prior art keywords
formula
preparation
macrocyclic
macrocyclic compounds
compounds
Prior art date
Application number
BRPI0607817-6A
Other languages
English (en)
Inventor
Fabrice Gallou
Azad Hossain
Suresh R Kapadia
Jianxiu Liu
Chris Hug Senanayake
Carl Alan Busacca
Nizar Haddad
Xudong Wei
Nathan K Yee
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0607817A2 publication Critical patent/BRPI0607817A2/pt
Publication of BRPI0607817B1 publication Critical patent/BRPI0607817B1/pt
Publication of BRPI0607817B8 publication Critical patent/BRPI0607817B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCESSO PARA A PREPARAçãO DE COMPOSTOS MACROCìCLICOS. A presente invenção refere-se a um processo para preparar um composto macrocíclico de fórmula (I) onde um composto macrocíclico hidroxil-substituído de fórmula (3) é reagido com um composto sulfonil-substituído de fórmula QUIN: Os compostos de fórmula (I) são agentes ativos potentes para o tratamento de infecção pelo vírus da hepatite O (HCV).
BRPI0607817A 2005-03-08 2006-03-06 compostos macrocíclicos e seu processo de preparação BRPI0607817B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65969605P 2005-03-08 2005-03-08
PCT/US2006/007954 WO2006096652A2 (en) 2005-03-08 2006-03-06 Process for preparing macrocyclic compounds

Publications (3)

Publication Number Publication Date
BRPI0607817A2 true BRPI0607817A2 (pt) 2009-10-06
BRPI0607817B1 BRPI0607817B1 (pt) 2019-11-26
BRPI0607817B8 BRPI0607817B8 (pt) 2021-05-25

Family

ID=36570780

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607817A BRPI0607817B8 (pt) 2005-03-08 2006-03-06 compostos macrocíclicos e seu processo de preparação

Country Status (17)

Country Link
US (2) US7608614B2 (pt)
EP (2) EP2332963A3 (pt)
JP (2) JP5667745B2 (pt)
KR (2) KR101514953B1 (pt)
CN (2) CN101160317B (pt)
AU (1) AU2006220708B9 (pt)
BR (1) BRPI0607817B8 (pt)
CA (1) CA2600367C (pt)
DK (1) DK1863833T3 (pt)
ES (1) ES2439732T3 (pt)
IL (2) IL185779A (pt)
MX (1) MX2007010879A (pt)
NZ (1) NZ562167A (pt)
PL (1) PL1863833T3 (pt)
RU (2) RU2456296C2 (pt)
WO (1) WO2006096652A2 (pt)
ZA (1) ZA200706560B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1753775B1 (en) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101294467B1 (ko) * 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008008502A1 (en) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2125113A2 (en) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US7932277B2 (en) 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
AU2008340257B2 (en) 2007-12-21 2015-06-11 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
EP2237666A4 (en) 2007-12-21 2012-05-16 Avila Therapeutics Inc HCV PROTEASE INHIBITORS AND USES THEREOF
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2282762A2 (en) 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2295969B1 (en) 2008-07-04 2016-05-18 Sekisui Medical Co., Ltd. Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2011006244A (es) 2008-12-10 2011-06-27 Achillion Pharmaceuticals Inc Nuevos peptidos de 4-amino-4-oxobutanoilo como inhibidores de replica viral.
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5647673B2 (ja) * 2009-05-05 2015-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロモ置換キノリンの調製方法
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112015007887A2 (pt) 2012-10-08 2017-07-04 Abbvie Inc compostos úteis para produzir inibidores hcv protease
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
KR20160005334A (ko) 2013-03-14 2016-01-14 아칠리온 파르마세우티칼스 인코포레이티드 소바프레비르 제조 방법
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
BR112015023351A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
CA2289709A1 (en) 1997-06-27 1999-01-07 Ciba Specialty Chemicals Holding Inc. Ruthenium and osmium catalysts
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE60129445T2 (de) * 2000-08-09 2008-04-24 F. Hoffmann-La Roche Ag Quinolin-derivate als antientzündungsmittel
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (zh) * 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
CN1771257A (zh) 2003-04-10 2006-05-10 贝林格尔·英格海姆国际有限公司 通过钌络合物催化的易位反应制备大环化合物的方法
JP4231524B2 (ja) 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EA009295B1 (ru) * 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
RS20110578A3 (en) * 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
BRPI0508867A (pt) * 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
BRPI0509467A (pt) * 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
EP1753775B1 (en) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
WO2006033851A1 (en) * 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Ring-closing metathesis process in supercritical fluid
JP2008513454A (ja) * 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法

Also Published As

Publication number Publication date
JP5667745B2 (ja) 2015-02-12
IL185779A (en) 2014-02-27
ES2439732T3 (es) 2014-01-24
MX2007010879A (es) 2007-11-23
US7608614B2 (en) 2009-10-27
EP2332963A3 (en) 2011-11-16
KR20140059308A (ko) 2014-05-15
CN101160317B (zh) 2013-03-27
WO2006096652A2 (en) 2006-09-14
DK1863833T3 (da) 2013-12-02
EP2332963A2 (en) 2011-06-15
IL228977A (en) 2015-11-30
WO2006096652A3 (en) 2006-11-23
RU2007136964A (ru) 2009-04-20
BRPI0607817B8 (pt) 2021-05-25
PL1863833T3 (pl) 2014-03-31
CA2600367A1 (en) 2006-09-14
CN103172697A (zh) 2013-06-26
US20060205638A1 (en) 2006-09-14
US20090326194A1 (en) 2009-12-31
KR20070117664A (ko) 2007-12-12
US8222369B2 (en) 2012-07-17
AU2006220708B2 (en) 2012-09-27
CA2600367C (en) 2014-08-12
ZA200706560B (en) 2008-09-25
IL228977A0 (en) 2013-12-31
NZ562167A (en) 2011-01-28
RU2456296C2 (ru) 2012-07-20
KR101514953B1 (ko) 2015-04-24
IL185779A0 (en) 2008-01-06
AU2006220708B9 (en) 2013-01-17
EP1863833B1 (en) 2013-09-18
BRPI0607817B1 (pt) 2019-11-26
RU2012113243A (ru) 2013-10-10
AU2006220708A1 (en) 2006-09-14
JP2008533014A (ja) 2008-08-21
EP1863833A2 (en) 2007-12-12
CN101160317A (zh) 2008-04-09
JP2012255030A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
BRPI0607817A2 (pt) processo para a preparação de compostos macrocìclicos
BRPI0508867A (pt) processo para a preparação de compostos macrocìclicos
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
BRPI0512659A (pt) compostos quìmicos
BR0309964A (pt) Derivados anticonvulsivos de sulfamoto substituìdo
BRPI0512060B8 (pt) compostos orgânicos, composições farmacêuticas compreendendo os mesmos, bem como uso e processo de preparação dos referidos compostos
BRPI0612104A8 (pt) composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
AR063706A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
BRPI0410238A (pt) compostos orgánicos
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
NO20092399L (no) Kjemiske forbindelser
BR0315781A (pt) Composição para tratamento de infecção causada por vìrus flaviviridae
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0416276A (pt) lactames macrocìclicos e uso farmacêutico dos mesmos
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
WO2008046860A3 (en) Bioavailable combinations for hcv treatment
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
BR0309753A (pt) Processo para a preparação de derivados de 6-alquilideno penem
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.1 NA RPI NO 2510 DE 12/02/2019 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2661 DE 04-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.